<DOC>
	<DOCNO>NCT00964704</DOCNO>
	<brief_summary>This single arm , open-label study evaluate safety efficacy Herceptin combination Avastin sequential Xeloda patient locally recurrent metastatic HER2-positive breast cancer early relapse adjuvant Herceptin therapy . Patients receive Herceptin load dose 8mg/kg iv follow 6mg/kg iv every three week , Avastin 15mg/kg every 3 week . At first sign disease progression Xeloda 1000mg/m2 bid po add day 1-14 cycle , docetaxel ( 100mg/m2 iv every 3 week ) Xeloda indicated patient . Anticipated time study treatment disease-progression second line treatment target sample size &lt; 100 .</brief_summary>
	<brief_title>A Study Herceptin ( Trastuzumab ) Combination With Avastin ( Bevacizumab ) Sequential Xeloda ( Capecitabine ) Docetaxel Patients With HER2-Positive Locally Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>male female patient , age &gt; /=18 year locally recurrent metastatic HER2positive breast cancer disease progression 12 month prior adjuvant therapy trastuzumab LVEF &gt; /=55 % baseline prior treatment bevacizumab capecitabine anthracyclines prior adjuvant neoadjuvant treatment exceed cumulative dose 360mg/m2 doxorubicin 720mg/kg epirubicin chronic daily treatment corticosteroid ( &gt; 10mg/day methylprednisolone equivalent ; exclude inhaled corticosteroid ) , aspirin ( &gt; 325mg/day ) , clopidogrel ( &gt; 75mg/day ) clinically significant cardiac disease , cardiac toxicity previous trastuzumab therapy evidence spinal cord compression CNS metastasis history malignancy , unless diseasefree &gt; /=5 year treat curatively carcinoma situ cervix nonmelanomatous skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>